From the Nov. 6, 2008 PR:
<During the third quarter, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients. The Phase IIb trial is expected to enroll approximately 480 patients in about 70 sites in the United States. Costs of $1,734,000 were incurred during the quarter in connection with the trial, comprising CRO-related activities and patient recruitment costs. The company is currently using two CRO's to enhance enrollment in the Phase IIb trial, using a variety of advertising tactics. The Company is currently behind its originally planned enrollment and now expects top line data to be available in the second half of 2009. Dextofisopam was one of the compounds the Company obtained through the acquisition of Vela Pharmaceuticals Inc which closed in October 2006. The continued development of this compound through late-stage clinical testing will increase the research and development expenses going forward.>

Now market capacity is $3.7M. Suppose the phase 2b trial will be successful what then is a reasonable market capacity?